Tumor hypoxia is associated with resistance to anti-angiogenic therapy and poor prognosis. The Siah E3 ubiquitin ligases regulate the hypoxic response pathway by modulating the turnover of the master pro-angiogenic transcription factor Hif-1α. In this study, we demonstrate that genetic deficiency in the Siah family member Siah2 results in vascular normalization and delayed tumor growth in an established transgenic model of aggressive breast cancer. Tumors arising in a Siah2 -/-genetic background showed increased perfusion and pericyte-associated vasculature, similar to that occurring with anti-angiogenic therapy. In support of the role of Siah2 in regulating levels of Hif-1α, expression of angiogenic factors was decreased in Siah2 -/-tumors. Blood vessel normalization in Siah2 -/-tumors resulted in an increased response to chemotherapy and prolonged survival.
Siah2 controls neoangiogenesis and responses to chemotherapy Abstract:
Tumor hypoxia is associated with resistance to anti-angiogenic therapy and poor prognosis. The Siah E3 ubiquitin ligases regulate the hypoxic response pathway by modulating the turnover of the master pro-angiogenic transcription factor Hif-1α. In this study, we demonstrate that genetic deficiency in the Siah family member Siah2 results in vascular normalization and delayed tumor growth in an established transgenic model of aggressive breast cancer. Tumors arising in a Siah2 -/-genetic background showed increased perfusion and pericyte-associated vasculature, similar to that occurring with anti-angiogenic therapy. In support of the role of Siah2 in regulating levels of Hif-1α, expression of angiogenic factors was decreased in Siah2 -/-tumors. Blood vessel normalization in Siah2 -/-tumors resulted in an increased response to chemotherapy and prolonged survival.
Together, our findings offer a preclinical proof of concept that targeting Siah2 is sufficient to attenuate HIF1α-mediated angiogenesis and hypoxia signaling, thereby improving responses to chemotherapy.
Siah2 controls neoangiogenesis and responses to chemotherapy
Siah2 controls neoangiogenesis and responses to chemotherapy is degraded by the 26S proteasome (8) . Under hypoxia, Hif-1α hydroxylation decreases due to reduced PHD abundance and activity (8) . We and others have shown that Siah proteins polyubiquitinate PHDs under hypoxic conditions (9, 10) , thereby targeting them for proteasomal degradation and allowing unmodified Hif-1α protein to dimerise with Hif-1β. The role of Siah proteins in tumor progression is becoming clearer (11) (12) (13) . Previously, we described that the loss of Siah2 reduces the occurrence of aggressive neuroendocrine tumors and metastasis of prostate adenocarcinoma (14) and Siah2 is required for melanoma metastasis through Hif-1 (15) .
Furthermore, a dominant negative version of Siah blocks oncogenic Ras signaling, thereby reducing pancreatic and lung tumor growth (16, 17) . We have previously described that inhibition of Siah2 by using a high affinity blocking peptide that binds to its substrate recognition domain can reduce growth and vascular development of tumors in a syngeneic and orthotopic breast cancer mouse model (18) . Importantly, we have shown that clinically, Siah2 protein expression is specifically increased in triple negative, basal-like breast cancer (19) . Here, we explore the growth and vascularization of breast cancer in Siah2 -/-mice in a PyMT transgenic background. We show that tumor growth is delayed in PyMT-Siah2 -/-animals. End-stage tumors show reduced angiogenic factor expression, as well as a vascular morphology resembling that seen following anti-VEGF treatment. We observe higher perfusion of PyMT-Siah2 -/-tumors which are more sensitive to doxorubicin-based chemotherapy. Our findings are the first to explore the effect of targeting the upstream regulator of the hypoxic response, Siah2, as an anti-tumoral strategy to achieve increased efficacy of conventional chemotherapy in an immune competent mouse model of cancer. This work has important implications for the utility of targeting this upstream regulator of hypoxia, angiogenesis and tumor cell survival.
Siah2 controls neoangiogenesis and responses to chemotherapy Material and Methods:
Animals: PyMT-Siah2 -/-and PyMT-WT mice were generated by crossing C57Bl/6 Siah2 -/-mice (20) 
Siah2 controls neoangiogenesis and responses to chemotherapy
Pharmingen: 550274), NG2 (Millipore; AB5320) and SMA (Dako; M0851) according to manufacturer's instructions and as described (18) . Texas-red dextran injections were done as described (22) . Pimonidazole (PIM) staining was carried out as described (23). Determination of CD31/NG2 co-localization and CD31/PIM minimum distances was done using Metamorph software in a semi-automated manner. 3-4 random fields of view per tumor were analyzed.
Proliferation and apoptosis were assessed by PCNA (BD Biosciences; 610665) and TUNEL (Chemicon) according to manufacturers' instructions. The positively stained cells were counted in 5 fields/mammary gland and expressed as percentage of total cells present.
Flow cytometry analysis. 3 rd and 4 th left and right mammary glands or endstage tumors were dissected, minced and then subjected to collagenase digestion before staining with APC-CD45, PE-F4/80 and PE-Cy7-CD11b antibodies prior to resuspension in FACS buffer containing 2% FBS and 1/100 dilution of 7AAD. The samples were analyzed on a BD FACSCanto II Loader machine.
Angiogenesis arrays, TIF. Tumor interstitial fluid (TIF) was prepared as described (24) . TIFs were then probed with mouse angiogenesis antibody proteome profiler array from R&D Systems according to manufacturer's instructions.
Western blot. Cells were treated as indicated, lysed and analyzed by Western Blotting as previously described (18) .
mRNA extraction and qPCR. mRNA from cells or tissues was isolated by QiaShredder (Qiagen) and RNeasy (Qiagen) kits according to the manufacturers' instructions.
Small animal PET and Ultrasound. 18 FAZA tracer was synthesized and labeled in a dedicated inhouse radiochemistry facility and injected into mice with 65 mm 3 tumors in their third mammary gland. 3 hours post injection mice were imaged on a prototype A-PET (Phillips Mosaic) small animal PET scanner as described (25) . A high-resolution small animal ultrasound system (Visualsonics, Inc.) was used to examine tumor vasculature and perfusion. In the 3D power Doppler acquisition mode, 2D images were acquired in 100 μm increments across the tumor and images stacked to produce a 3D representation of the tumor. Percent vasculature was then calculated as the
ratio of the number of colored voxels within the tumor volume and the total number of voxels within the same volume. Perfusion was evaluated in the centre slice of the tumor using a destruction/replenishment technique employing microbubbles as described previously (26) . 
Clonogenic
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Results:
Loss of Siah2 delays tumor onset
We investigated the impact of Siah2 in breast cancer progression by generating MMTVPolyoma Middle T (PyMT) transgenic mice on a Siah2 -/-background. Loss of Siah2 resulted in a significantly increased time to tumor onset compared to PyMT-wild type animals (PyMT-WT; 81 days of age; PyMT-Siah2 -/-; 121 days of age; p<0.001; Figure 1A ). To determine whether this delay can also be seen at earlier stages, we next examined the mammary glands of mice before the onset of palpable tumors. Mammary gland whole mounts ( Figure 1B and Supplementary Figure 1A While there was a trend towards longer time to ethically allowed endpoint (525 mm 3 ) in Siah2 -/-mice, this was not statistically significant (p=0.36; Figure 1D ). Although initially delayed, once tumors became palpable in Siah2 -/-animals, they grew rapidly ( Figure 1E ). This data suggest
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that the initial delay of tumor growth initiation in PyMT-Siah2 -/-mice is associated with early events in tumor development but compensatory changes allow accelerated growth of the tumor.
Reduced stromal infiltration in Siah2 -/-breast tumors:
Tumors in PyMT-WT mice were typically fluid or blood-filled, had a high degree of stromal infiltration and large areas of necrosis ( Fig 5B) . In contrast, PyMT-Siah2 -/-tumors showed significantly more pericyte coverage of endothelial cells ( Figure 3B and Supplementary Fig   5B) , which is characteristic for more mature vessels (1).
To examine if these different vessel phenotypes are functionally similar, we injected Texas
Red Dextran into the blood stream of tumor-bearing mice. By this method only blood-carrying vessels are labeled (22) . PyMT-Siah2 -/-tumors contain significantly more blood-carrying vessels compared with PyMT-WT tumors in both spontaneous and transplanted tumor models ( Figure 3C and data not shown). To further corroborate this observation, blood flow and perfusion was assessed by high resolution 3D power Doppler ultrasound (32) . For this experiment, single large tumors are required, rather than multiple foci occurring in the spontaneous model. Therefore, tumor cells derived from PyMT-WT and PyMT-Siah2 -/-mice were injected into the 4 th mammary fatpad of syngeneic mice (named PyMT-WT/WT and PyMT-Siah2 -/-/KO, respectively). Tumors generated this way recapitulated the angiogenic, pericyte and stromal infiltration phenotypes observed in the spontaneous model (data not shown). In tumors of similar size (approximately 150 mm 3 , Figure   3D ), PyMT-Siah2 -/-/KO tumors had a significantly increased percentage of functional, bloodcontaining vasculature compared to those in PyMT-WT/WT tumors ( Figure 3E ). Furthermore, Siah2 controls neoangiogenesis and responses to chemotherapy using replenishment kinetics following an ultrasound-induced destruction of microbubbles, we observed significantly elevated perfusion of the PyMT-Siah2 -/-/KO tumors ( Figure 3F ).
To assess if increased tumor perfusion impacted on tumor-associated hypoxia, PyMT-WT and PyMT-Siah2 -/-tumors were investigated by small animal PET using the hypoxia tracer 18 FAZA.
PyMT-Siah2 -/-tumors showed a trend towards reduced hypoxia ( Figure 4A , p=0.09). The tissue localization of hypoxic areas was visualized using the hypoxia marker pimonidizole (PIM), which accumulates preferentially in areas of limited perfusion (25, 33) . Co-staining with PIM and the vascular marker CD31 showed that in PyMT-Siah2 -/-tumors, hypoxia was restricted to regions that were predominantly distant from blood vessels ( Figure 4B and Supplementary Figure 6A PyMT-Siah2 -/-mice compared to PyMT-WT mice ( Figure 4C ). Hif-1α is responsible for the induction of a wide range of pro-angiogenic factors, including VEGF and angiopoetins (36) and the phenotypes observed above suggest that the loss of Siah2 in tumor cells causes an angiogenic normalization phenotype similar to VEGF inhibition. We therefore assessed the levels of VEGF and
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the VEGF receptors, Kdr (VEGFR2) and Flt1 (VEGFR1), as well as several FGFs and angiopoetin expression in the two tumor genotypes by qPCR. Expression of these pro-angiogenic factors was either similar in both tumor genotypes or significantly reduced in PyMT-Siah2 -/-tumors ( Figure   4D ). These results demonstrated that the previously described hypoxia response-dependent proangiogenic pathway is largely suppressed in PyMT-Siah2 -/-tumors. To uncover the mechanism and factors utilized by PyMT-Siah2 -/-tumors to induce vessel formation, we used a proteomic approach to screen for angiogenic factors secreted at elevated levels into the tumor interstitial fluid (TIF) by
PyMT-Siah2 -/-tumors. We found variations between amounts and composition of angiogenic factors secreted from tumors of the same genotype attributable to the heterogeneity of this model (37) . However, we found that PyMT-WT TIFs derived from both small (65mm Figure 6B) . This data suggests that the difference in angiogenesis in the PyMT-Siah2 -/-tumors is not due to reduced macrophage infiltration causing changes to the angiogenic switch. 
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Malignant tumor progression past an initial "avascular phase" requires new blood vessel formation once the tumor grows beyond 500 μm in diameter (38) . Hypoxia is a key driver in the neo-angiogenic process required to form a new but inefficient tumor-associated vasculature network (39) . While no single protein seems to be the master regulator of neo-angiogenesis, the loss or inhibition of VEGF or its kinase receptors (VEGF-Rs) results in a normalization of the tumor vasculature. As a normalized vasculature would lead to more efficient delivery of blood through tumor-associated vessels, anti-angiogenic therapy might result in higher sensitivity of tumors to standard chemotherapy (40) . This prediction has since been verified in animal models in which VEGF or VEGF-R function has been attenuated. More recently, anti-VEGF treatment of glioblastoma patients has been associated with improved tumor perfusion and enhanced survival been proven in glioblastoma patients (41) . Anti-angiogenic therapy through EGFR inhibition with erlotinib was also shown to result in increased sensitivity towards chemo-and radiotherapy (42) .
Similarly, we find in this study that the loss of Siah2 results in vascular normalization, increased tumor perfusion and elevated sensitivity to doxorubicin-based chemotherapy (Summarized in the schematic in Figure 5E ).
Although blocking proteins downstream of Hif-1α, such as VEGF, is an attractive therapeutic approach, the clinical success of anti-angiogenic therapies has been limited. Hif-1
regulates a wider range of responses that allow cancer cells to survive in hypoxic environments and it appears that targeting just a subset of these allows the emergence of bypass mechanisms and restoration of tumor growth (6) . In addition, inhibition of single Hif-1 targets may leave other hypoxic responses, such as metastatic spread, uncontrolled or enhanced, with unintended consequences for patients (43, 44) . For these reasons, targeting the Hif-1α protein directly represents a promising approach that should be explored in more detail.
As a transcription factor, targeting Hif-1 activity directly is difficult and most drugs that inhibit Hif-1α activity do so by altering other signaling pathway components that influence Hif-1α 
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Siah has been linked to Hif-1α dependent and independent mechanisms (15, 17) . However, untangling the relative contribution of inhibition to each of these pathways to attenuation of tumor growth is challenging (12) .
We have previously generated the peptide-based Siah inhibitor PHYL (18, 53) 
